Background and study aims Chromoendoscopy with targeted biopsy is the technique of choice for colorectal cancer screening in longstanding inflammatory bowel disease. We aimed to analyze results of a chromoendoscopy screening program and to assess the possibility of identifying low-risk dysplastic lesions by their endoscopic appearance in order to avoid histological analysis. Materials and methods We retrospectively reviewed chromoendoscopies performed between February 2011 and June 2017 in seven Spanish hospitals in a standardized fashion. We analyzed the findings and the diagnostic yield of the Kudo pit pattern for predicting dysplasia. Results A total of 709 chromoendoscopies (569 patients) were reviewed. Median duration of disease was 16.7 years (SD 8.1); 80.4 % had ulcerative colitis. A total of 2025 lesions (3.56 lesions per patient) were found; two hundred and thirty-two lesions were neoplastic (11.5 %) (223 were LGD (96.1 %), eight were HGD (3.4 %), and one was colorectal cancer (0.5 %). The correlation between dysplasia and Kudo pit patterns predictors of dysplasia (≥ III) was low, with an area under the curve of 0.649. Kudo I and II lesions were correctly identified with a high negative predictive value (92 %), even by non-experts. Endoscopic activity, Paris 0-Is classification, and right colon localization were risk factors for dysplasia detection, while rectum or sigmoid localization were protective against dysplasia. Conclusions Chromoendoscopy in the real-life setting detected 11 % of dysplastic lesions with a low correlation with Kudo pit pattern. A high negative predictive value would prevent Kudo I and, probably, Kudo II biopsies in the left colon, reducing procedure time and avoiding complications.
Aims: To determine risk factors for active tuberculosis in patients with inflammatory bowel diseases.Methods: Retrospective, case-control study at 4 referral hospitals in Spain. Cases developed tuberculosis after a diagnosis of inflammatory bowel disease. Controls were inflammatory bowel disease patients who did not develop tuberculosis. For each case, we randomly selected 3 controls matched for sex, age (within 5 years) and time of inflammatory bowel disease diagnosis (within 3 years). Inflammatory bowel disease characteristics, candidate risk factors for tuberculosis and information about the tuberculosis episode were recorded. Multivariate analysis and a Chi-squared automatic interaction detector were used.Results: Thirty-four cases and 102 controls were included. Nine of the 34 cases developed active tuberculosis between 1989 and 1999, and 25 became ill between 2000 and 2012. Multivariate regression showed an association between active tuberculosis and anti-TNF (tumor necrosis factor) therapy in the previous 12 months (OR 7.45; 95% CI, 2.39-23.12; p = 0.001); hospitalization in the previous 6 months (OR 4.38; 95% CI, 1.18-16.20; p = 0.027); and albumin levels (OR 0.88; 95% CI, 0.81-0.95; p = 0.001). The median time between the start of biologic therapy and the onset of active tuberculosis was 13 (interquartile range, 1-58) months. Tuberculosis developed after a year of anti-TNF therapy in 53%, and late reactivation occurred in at least 3 of 8 patients.Conclusions: The main risks factors for developing tuberculosis were anti-TNF therapy and hospitalization. Over half the cases related to anti-TNF treatment occurred after a year.
Background Ustekinumab is an effective drug in Crohn′s Disease (CD) and most frequently used dose is subcutaneous (sc), 90 mg /, 8 weeks. With the usual sc doses (90 mg every, 8–12 weeks) some patients will only partially respond or experience secondary loss of response. In this situation, shortening of the administration interval (e.g., every, 4 or, 6 weeks) or a reinduction dose has been proposed. Another unexplored option is intravenous (IV) administration at regular intervals when shortening sc dose is not effective enough. Methods We conducted a retrospective study to evaluate the effectiveness of IV ustekinumab at regular intervals (usually every, 4–6 weeks) in patients with insufficient efficacy or loss of response to, 90 mg sc every, 4–6 weeks. All patients had active Ulcerative colitis (UC) or Crohn′s disease (CD) defined by partial Mayo score (pMS) or Harvey Bradshaw Index (HBI)>, 4 points and/or persistent biomarker elevation (calprotectin>, 250 µg/g) and/or endoscopic or radiological evidence of disease activity. We obtained data from, 79 patients (73 CD and, 6 with ulcerative colitis (UC)). Levels of fecal calprotectin before and after starting ustekinumab IV was available for, 44 patients and trough levels of drug for, 48 patients. Results Baseline characteristics of the included patients are shown in Table, 1. Complicated forms (B2-B3;, 60,6%) predominated and perianal disease was present in, 35.4% of patients. Only, 3 patients were naïve to biological treatments, 41.8% had received at least one and, 54,5% more than, 2. The mean follow-up after the first IV administration was, 13.22 months (IQR, 2–37 months). Last dose used before the start of ustekinumab IV was, 90 mg /, 6 weeks in, 31.6% and, 90 mg /, 4 weeks in, 68.4% of the patients. After, 12 weeks of the first IV dose, 43% of patients achieve clinical remission (HBI<5 or pMS, 2) and, 59.5% at the end of follow-up. Basal fecal calprotectin decreased significantly at month, 12 and at end of follow-up (612.6 mg/kg vs, 384.1 mg/kg vs, 222 mg/kg; p = 0.0002 and p=0,0048 respectively) (Figure, 1). Drug levels at the beginning of IV administration were, 2.6 mcg/ml (IQR, 0.13-11-69) and a significant increase from baseline was observed (week, 12–16:, 9.09 mcg/ml and after, 1 year:, 10.7 mcg/ml; both p <0,001). At the end of the follow-up, 81% of patients maintain the treatment (figure 2). Conclusion Patients who lose response to the intensified dose of ustekinumab sc could benefit from intravenous administration as maintenance treatment. This strategy achieves clinical remission in, 60% of the patients and allows to maintain the treatment in, 80% of them for at least, 12 months.
A clinical trial comparing propofol versus propofol plus midazolam in diagnostic endoscopy of patients with a low anesthetic risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.